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Abstract: Disulfiram (DS), an anti-alcoholism medicine, shows strong anti-cancer activity
in the laboratory, but the application in clinics for anti-cancer therapy has been limited
by its prompt metabolism. Conventional liposomes have shown limited ability to protect
DS. Therefore, the aim of this study is to develop PEGylated liposomes of DS for
enhanced bio-stability and prolonged circulation. PEGylated liposomes were prepared
using ethanol-based proliposome methods. Various ratios of phospholipids, namely:
hydrogenated soya phosphatidylcholine (HSPC) or dipalmitoyl phosphatidylcholine (DPPC)
and N-(Carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine
(DSPE-PEG2000) with cholesterol were used. DS was dissolved in the alcoholic solution in different
lipid mol% ratios. The size of the resulting multilamellar liposomes was reduced by high-pressure
homogenization. Liposomal formulations were characterized by size analysis, zeta potential, drug
loading efficiency and stability in horse serum. Small unilamellar vesicles (SUVs; nanoliposomes)
were generated with a size of approximately 80 to 120 nm with a polydispersity index (PDI) in the
range of 0.1 to 0.3. Zeta potential values of all vesicles were negative, and the negative surface charge
intensity tended to increase by PEGylation. PEGylated liposomes had a smaller size (80–90 nm)
and a significantly lower PDI. All liposomes showed similar loading efficiencies regardless of lipid
type (HSPC or DPPC) or PEGylations. PEGylated liposomes provided the highest drug biostability
amongst all formulations in horse serum. PEGylated DPPC liposomes had t1/2 =77.3 ± 9.6 min
compared to 9.7 ± 2.3 min for free DS. In vitro cytotoxicity on wild type and resistant colorectal cancer
cell lines was evaluated by MTT assay. All liposomal formulations of DS were cytotoxic to both the
wild type and resistant colorectal cancer cell lines and were able to reverse chemoresistance at low
nanomolar concentrations. In conclusion, PEGylated liposomes have a greater potential to be used as
an anticancer carrier for disulfiram.
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1. Introduction
The medical need for better cancer therapies is undiminished, while drug development is slow
and costly, mainly due to the large risk of toxicity of novel molecules. Development of a new
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drug takes, on average, 15 years and costs US$1.5bn, with only 5–25% of new oncology drugs in
clinical development actually reaching the market [1]. This dilemma has led to a booming interest in
repurposing of known drugs into new use in Europe and the USA [2]. Currently, over 30,000 drugs
have been on the market. Considering their derivatives, this is a tremendously huge resource for
drug repositioning.
Disulfiram (DS, Figure 1), a well-known anti-alcoholism drug that has been used safely for over
65 years, has shown potent anticancer activity against the aggressive form of colon, breast, lung,
prostate, ovarian, cervical and brain cancers. Furthermore, this drug specifically and effectively
terminates drug-resistant cancer stem cells (CSCs) and reverse chemoresistance [3,4]. DS also has
a significant synergic cytotoxicity with a wide range of first-line anticancer drugs such as cisplatin,
5-flurouracil, paclitaxel, gemcitabine, doxorubicin and temozolomide in vitro and saves normal cells in
kidney, gut and bone marrow in vivo by increasing the therapeutic index [5–7]. The anticancer activity
of DS is copper (II)-dependent as DS strongly chelates Cu to form a DS/Cu complex [8] (Figure 1).
Cancer tissues possess significantly higher copper levels than their normal counterparts [9]; this may
grant DS the selectivity to target cancer cells [10]. Although DS shows strong anticancer activity in
laboratory, its application in cancer clinics is highly limited by its bio-instability. The half-life of DS in
the blood stream is less than 4 min [11,12].
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Liposomes are nanocarrier systems made of relatively stable and cheap compositions and
prepared by hydration of phospholipids known to be non-toxic, biodegradable, biocompatible,
and non-immunogenic [15,16]. The unique structures of liposomes make them capable of encapsulating
both hydrophilic and lipophilic drugs [17,18]. For example, Wang et al. have successfully encapsulated
DS into liposome (Lipo-DS) and managed to mildly extend the half-life of DS in the bloodstream
to approximately 20 min [3,19]. However, more development is required in this field, especially for
enhancing the loading efficiency and extending the stability of DS [14]. For example, developing
long-circulating drug delivery systems that might have a potential for translation to cancer therapy.
Furthermore, the instability of liposomes owing to liability of its compositions to hydrolysis, oxidation
and microbiological contamination needs to be overcome.
One approach to preparing liposomes is by using the proliposome technology as
stable precursors that can instantly generate vesicles prior to formulation administration [20].
Ethanol-based proliposomes are based on using ethanolic lipid solutions to facilitate the hydration
of phospholipids and generate oligolamellar or multilamellar liposome vesicles [21]. Proliposomes
represent an economical approach to scale-up liposome production and resolve the instability problems
associated with conventional thin-film-made liposomes. These advantages are attributed to the
predominance of the ethanolic phase in proliposomes instead of water, avoiding phospholipid
hydrolysis and offering self-antimicrobial preservation [22,23].
In this study, we have developed injectable DS-loaded PEGylated liposomes for colorectal cancer
treatment. Ethanol-based proliposome technology was used to prepare DS-loaded liposomes with
various lipid compositions. The prepared formulations were characterized by particle size; particle
size distribution; zeta potential and drug entrapment efficiency. Additionally, the cytotoxicity of the
PEGylated liposome encapsulated DS was examined in both 5-fluorouracil sensitive (H630WT) and
resistant (H630R10) colon cancer cell lines.
2. Materials and Methods
2.1. Materials
Hydrogenated phosphatidylcholine (HSPC; Phospholipon 90H), dipalmitoyl
phosphatidylcholine (DPPC) and N-(Carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-
glycero-3-phosphoethanolamine, (DSPE-PEG2000) were obtained from Lipoid, Steinhausen,
Switzerland. Tetraethylthiuram disulfide or disulfiram (DS) (97% pure) and Tween® 80 were
purchased from Acros Organics, Loughborough, UK. Dulbecco’s modified Eagle’s medium (DMEM),
non-essential amino acid solution and L-glutamine (cell culture tested, 99.0–101.0%), Trypsin-EDTA
solution, ethanol (absolute and 70%), 96-well plates (sterile with lids), 50 mL centrifuge tubes (sterile),
tissue culture flask 75 cm2 (sterile) and serological pipettes (sterile) were obtained from Fisher Scientific,
Loughborough, UK. Cholesterol (Ch; ≥ 99%), glass vials (15 mL), fluorouracil (5FU), dimethyl sulfoxide
(DMSO), thiazolyl blue tetrazolium bromide, fetal bovine serum (FBS), phosphate-buffered saline (PBS)
tablets, trypan blue solution (0.4% liquid, sterile filtered), syringe filters (0.2 and 0.45 µm), syringe
needles and sterile pipette tip boxes were purchased from Sigma Aldrich, Dorset, UK. Horse Serum,
New Zealand origin was purchased from Gibco, Fisher Scientific, Loughborough, UK. Colorectal
cell line (H630WT) and acquired resistance to 10 µM 5FU colorectal cell line (H630R10) were obtained
from Professor Weiguang Wang Group, University of Wolverhampton, Wolverhampton, UK. All other
reagents were of pharmaceutical grade and used as received.
2.2. Methods
2.2.1. Preparation of Liposomes
Liposomal formulations were prepared using the ethanol-based proliposome method reported
previously [20]. The lipid phase (phospholipid: Ch; 1:1 mole ratio) (300 mg) was dissolved in absolute
Pharmaceutics 2019, 11, 610 4 of 16
ethanol (300 µL) at 70 ◦C (water bath) for 1 min within a 30 mL glass vial. For the PEGylated liposomes,
the ratio was DSPE-PEG2000: phospholipid: Ch, 0.1:0.9:1 mole ratio. Disulfiram (DS) was then added
in the ethanolic solution to produce a range of concentrations as mol% of the ultimate lipid phase
(0, 5, 10 and 15 mol% of the lipid phase, Table 1). Aqueous (water) phase (30 mL), heated significantly
above the Tm of the lipid, was added immediately to avoid lipid phase solidification. Liposomes were
generated upon vigorous hand shaking and vortex mixing (Grant-bio PV-1, Shepreth, UK) for 5 min.
Liposomal formulations were then kept for annealing above the phase transition temperature of the
lipids for 2 h followed by size reduction.
Table 1. The ingredients of DS liposomal formulations.
Formulation
Ingredients
DSPE-PEG2000 HSPC DPPC Ch DS
HSPC:Ch
0.0 (mol% *) - 1 ** - 1 -
5.0 - 1 - 1 0.11
10.0 - 1 - 1 0.22
15.0 - 1 - 1 0.36
PEG:HSPC:Ch
0.0 0.1 0.9 - 1 -
5.0 0.1 0.9 - 1 0.11
10.0 0.1 0.9 - 1 0.22
15.0 0.1 0.9 - 1 0.36
DPPC:Ch
0.0 - - 1 1 -
5.0 - - 1 1 0.11
10.0 - - 1 1 0.22
15.0 - - 1 1 0.36
PEG:DPPC:Ch
0.0 0.1 - 0.9 1 -
5.0 0.1 - 0.9 1 0.11
10.0 0.1 - 0.9 1 0.22
15.0 0.1 - 0.9 1 0.36
* Drug lipid molar percentage. ** Molar ratio.
2.2.2. Size Reduction of Liposomes
Liposome dispersions (30 mL, 10 mg formulation/mL) was placed in the bench top NanoDebee
high-pressure homogenizer (Bee International Inc., Northampton, UK) and processed for 10 cycles
through seven reactors at 20,000 psi. Thereafter, liposome dispersions were placed on a magnetic
stirring plate at 350 rpm in a fume-hood to stir for 5 h to minimize the trace amounts of ethanol in
the formulation.
2.2.3. Photon Correlation Spectroscopy (PCS) Analysis after Size Reduction
The photon correlation spectroscopy (PCS) technique relies on the Brownian motion of the particles
using the Zetasizer instrument (Zetasizer nano, Malvern Instruments Ltd., Malvern, UK). The size and
polydispersity of the homogenized liposomes were analyzed by recording the hydrodynamic diameter
(Zaverage) and polydispersity index (PI), respectively, using the Zetasizer instrument (Zetasizer nano,
Malvern Instruments Ltd., Malvern, UK).
2.2.4. Determination of Drug Entrapment Efficiency
Entrapment efficiency of DS was determined by adapting the separation methods previously
reported [24,25]. One mL of liposome suspension was passed through a syringe filter (Durapore®
Membrane PVDF Filters, HVLP02500, 0.45 µm, Hertfordshire, UK) followed by injecting 2 mL distilled
water to wash the filter. The filtrate (0.5 mL) was add to 1.5 mL of methanol. The mixture was bath
sonicated (Fisherbrand™ 112201, Loughborough, UK) for 2 min to disrupt the liposomes and release
the entrapped drug. To determine the total amount of DS in liposome formulation, 1 mL was diluted
directly by 2 mL distilled water, and 0.5 mL of the resulting suspension was treated by methanol
following the same steps described above. HPLC analysis reported by Najlah et al. [14] was performed
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on an UltiMate 3000 UHPLC (Thermo Fisher Scientific UK, Loughborough, UK) with a Phenomenex
Luna C18 4.6× 150 mm column with a 5 µm particle size (Phenomenex, Torrance, CA, USA). The mobile
phase comprised 80% HPLC grade methanol and 20% HPLC grade water. The flow rate was 1 mL/min,
whereas UV detection was performed at a wavelength of 275 nm with an injection volume of 20 µL.
The solubility of DS in water is less than 4.5 mg/L [11,26,27]. Therefore, the amount of the drug
dissolved in water during hydration was ignored. However, any traces solubilized during the process
were excluded by following the same dilution factor for both the entrapped and total drug calculations.
The entrapment efficiency (EE) of DS in liposomes was calculated using the following equation:
EE (%) = (Amount of DS entrapped/Total amount of DS in liposomal suspension) × 100
The drug loading efficacies (DLE%) were calculated by the following equation [28]:
DLE (%) = (Amount of DS entrapped/Theoretical DSF content in liposome) × 100%
2.2.5. Stability of Encapsulated Disulfiram in Horse Serum
A sample (0.5 mL) of liposome formulation (10 mol% formulation) was preheated at 37 ◦C, added
to 2 mL of horse serum (preheated at 37 ◦C) and incubated in a shaking water bath at 37 ◦C (Grant OLS
Aqua Pro, Shepreth, UK) and 100 rpm. For free DS, 25 µL of 4 mg/mL DS in DMSO was pipetted in
to 2 mL of horse serum diluted with 475 µL of distilled water (preheated at 37 ◦C). At specific time
intervals, aliquots of 200 µL were added to 500 µL of ethanol and vortexed for 1 min. The mixture
solution was centrifuged at 10,000× g for 10 min (Heraeus Fresco 17, UK). The supernatant “A” was
collected and the pellet was re-suspended in 0.5 methanol vortex for 30 s and heated in the water bath
37 ◦C for 2 min, then vortexed for 30 s again and centrifuged at 10,000× g for 10 min. The supernatant
“B” was collected, added to supernatant “A” and analyzed by HPLC using the methods reported above.
For the control, the same formulation and previous steps were followed, but by replacing the horse
serum with distilled water. The control was used as 100% for the stability calculations.
2.2.6. Cytotoxicity Study (MTT Assay)
The H630WT (passage 13–27) and H630R10 (passage 4–16) cells were seeded in 96-well plates
at seeding density of 1 × 104 cells/well in Dulbecco’s modified Eagle’s medium (DMEM) with 10%
FBS, 1 mM sodium pyruvate, 2 mM L-glutamine and 0.1 mM non-essential amino acids. Cells were
incubated at 37 ◦C, 5% CO2 and 95% relative humidity. Cells were constantly exposed to different
concentrations of the 10% w/w DS-loaded liposomes in combination with 10 µM of CuCl2 for 72 h
and then subjected to a standard 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium bromide (MTT)
assay as previously described [29]. Free DS has been used as a positive control. The experiments
were carried out in triplicates and the IC50 values were calculated. For combination studies, cells
were exposed simultaneously to similar concentration range of DS and paclitaxel (1–250 nM) and DS
(1–250 nM) and 5FU (1–250 µM).
2.2.7. Statistical Analysis
Statistical significance was measured using the one-way analysis of variance (ANOVA) and
student’s t-tests, as appropriate. All values were expressed as the mean ± standard deviation.
Values with p < 0.05 were regarded as significantly different.
3. Results and Discussion
Several DS liposomal formulations were prepared using three phospholipids HSPC, DDPC or
DSPE-PEG2000, with cholesterol (Ch) in 50:50 lipid:Ch molar ratios (Table 1). We have reported in
a previous study that liposomes prepared at an equimolar ratio of lipid:Ch using ethanol-based
proliposome technology were able to act as potential carrier of the highly hydrophobic anticancer
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drugs [20]. DS was included in the liposomal formations at a molar percentage ranging from 0 to
15 (mol%) of the lipids (Table 1).
3.1. Size Analysis of Liposomes
In recent decades, a few techniques have been predominantly employed to reduce the size of
liposomes into the nano range, such as probe sonication [30], membrane extrusion [31] and high-pressure
homogenization [32]. We have previously reported that high-pressure homogenization (HPH) might be
more advantageous than probe sonication; HPH produced vesicles with a similar drug entrapment
efficiency and superior homogenization output rate [23]. Furthermore, HPH overcame problems
associated with probe sonication such as sample contamination (with titanium particles leached from
the probe) and overheating [23]. In this study, HPH was used to reduce the size of liposomes and
transform large multilamellar vesicles (MLVs) into smaller unilamellar vesicles (SUVs, ~100 nm).
As shown in Figure 2a, HPH was successfully employed to produce liposomes with a range of
sizes around 100 nm. For all formulations, the drug inclusion had no significant impact on liposome
size (p > 0.05). Similarly, the size of produced vesicles was not affected by lipid phase composition as
there were no significant difference (p > 0.05) amongst HSPC formulations and their corresponding
DPPC formulations. Noteworthy, the average size of non-PEGylated formulations (both HSPC and
DPPC) was about 100 nm, while the average size of PEGylated formulations was around 80 nm.
This might be considered as a general trend that similar size reduction methods can produce PEGylated
liposomes that are smaller than their non-PEGylated counterparts. This trend has been confirmed in the
literature and explained by the increased intensity of lateral repulsion caused by the addition of PEG
to the lipid bilayers (i.e., the lipid bilayer will curve; this will reduce the size of vesicle). Furthermore,
PEGylation decreases lamellarity as a result of increased interlamellar repulsion [33]. Nonetheless,
in this study, no significant difference was proven by the statistics (Figure 2a).
Pharmaceutics 2019, 11, x  6 of 16 
 
3.1. Size Analysis of Liposomes 
In recent decades, a few techniques have been predominantly employed to reduce the size of 
liposomes into the nano range, such as probe sonication [30], membrane extrusion [31] and high-
pressure homogenization [32]. We have previously reported that high-pressure homogenization 
(HPH) might be more advantageous than probe sonication; HPH produced vesicles with a similar 
drug entrapment efficiency and superior homogenization output rate [23]. Furthermore, HPH 
overcame problems associated with probe sonication such as sample contamination (with titanium 
particles leached from the probe) and overheating [23]. In this study, HPH was used to reduce the 
size f liposomes and transform large multilamellar vesicles (MLVs) into smaller unilamellar vesicles 
(SUVs, ~100 ). 
As shown in Figure 2a, HPH was successfully employed to produce liposomes with a range of 
sizes around 100 nm. For all formulations, the drug inclusion had no significant impact on liposome 
size (p > 0.05). Similarly, the size of produced vesicles was not affected by lipid phase composition as 
there were no significant difference (p > 0.05) amongst HSPC formulations and their corresponding 
DPPC formulations. Noteworthy, the average size of non-PEGylated formulations (both HSPC and 
DPPC) was about 100 nm, while the average size of PEGylated formulations was around 80 nm. This 
might be considered as a general trend that similar size reduction methods can produce PEGylated 
liposomes that are smaller than their no -PEGylated counterparts. This trend has been confirmed in 
the literature and explained by the increased int nsity of lateral repulsion caused by the addi ion of 
PEG to the lipid bilayers (i.e., the lipid bilayer will curve; this will reduce the size of vesicle). 
Furthermore, PEGylation decreases lamellarity as a result of increased interlamellar repulsion [33]. 
Nonetheless, in this study, no significant difference was proven by the statistics (Figure 2a). 
 
Figure 2. Size (Zaverage) (a) and PI (b) of liposomes after high-pressure homogenization with a range of 
DS concentrations (n = 3 ± SD). 
Figure 2. Size (Zaverage) (a) and PI (b) of liposomes after high-pressure homogenization with a range of
DS concentrations (n = 3 ± SD).
Pharmaceutics 2019, 11, 610 7 of 16
It has been reported that the size of liposomes might be influenced by the degree of phospholipid
saturations, and the charge and/or the length of the chain of their lipid components [20,34,35]. In this
study, the only difference between both phospholipids is the chain length (16 and 18 for DPPC and
HSPC, respectively); hence, no significant changes in the measured size were shown. Differently,
we have reported previously that paclitaxel (PTX)-loaded liposomes made from HSPC had larger
sizes than that made from DPPC [20]. This might be due to different strength in drug–lipid-bilayer
interactions between both sets of formulations.
HPH has also generated liposomes with relatively narrow size distribution (i.e., low PI), regardless
of lipid type, PEGylation and drug concentration (Figure 2b). The polydispersity index (PI) for all
liposomes was found to be below 0.35 (Figure 2b). However, PEGylation was found to produce
liposomes of narrower PIs (p < 0.05) than that of the conventional PEGylated liposomes, regardless
of lipid type and drug concentration (Figure 2b). This is attributed to the superiority of PEGylated
liposomes over conventional vesicles [36,37]. For non-PEGylated liposomes, the inclusion of DS
resulted in liposomes with narrower PIs than that of empty liposomes. Surprisingly, no similar
trend was observed for the PEGylated liposomes. This might be due to a less effective drug–bilayer
interaction compared to the effect of PEGylation, leading to better curving of the bilayer, as explained
above. It is noteworthy to mention that PI was independent of drug concentration for all loaded
formulations (Figure 2b).
During the development stage of this method, our results showed that PI and size measurements
were dependent on the number of homogenization cycles up to a certain number (data not shown).
Conclusively, the low PI for all formulations indicates that the number of cycles selected was appropriate
and no further high-pressure homogenization was required.
3.2. Zeta Potential Analysis
The zeta potential (ZP), the electrostatic charge of the particle surface, plays an important role
in controlling the stability of colloids by the repulsive energy barrier opposing the aggregation of
dispersed particles (e.g., liposomes) in buffer solutions [37,38]. The ZPs of all liposomes were negative,
irrespective of formulation. Furthermore, for all formulations, insignificant effects (p > 0.05) of drug
concentration on the zeta potential were observed (Figure 3). This may indicate that HPH produced
stable nano-liposomes vesicles, as the electrostatic repulsion between negatively charged vesicles may
reduce aggregation [38].
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PEGylation of DS-free liposomes resulted in a significant increase (p < 0.05) in the negativity
of zeta potential for both phospholipids. However, despite the apparent differences in ZP values
between PEGylated and non-PEGylated DS-liposomes, no statistically significant differences amongst
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DS-loaded liposomes were found. Nevertheless, this might suggest that ZP values might be affected
by vesicle size [38].
3.3. Drug Loading and Entrapment Efficiencies of DS in Liposomes
In a liposomal dispersion, drug is expected to be entrapped in the liposomal vesicles (in the core
for hydrophilic drugs or embedded within the lipid bilayer for hydrophobic drugs). Additionally,
this process depends on many factors such as the ion strength and the pH of the aqueous phase,
the incubation time, the drug to lipid loading ratio, the lipid composition and other [39]. However,
the excess amount normally remains as crystals suspended, aggregated (within the aqueous phase),
or sedimented [40]. During HPH, samples are forced under high pressure through a narrow nozzle
orifice followed by several narrow gaps created by the reactors. Samples are then collected and
returned to the feeding chamber to start the next cycle. During this process, unentrapped drug particles
may be filtered out of the liposomal formulations and trapped between the reactors and in the tubing.
Therefore, it is very important to develop methods that can capture both the amount entrapped by
liposomes and the actual total amount in the liposomal formulation (the entrapped plus the free drug).
To present an accurate description of loading amounts of DS to liposomes, two efficiencies were
calculated. Namely, (1) Drug Loading Efficiency (DLE%) to calculate the amount of drug loaded into
liposomes out of the theoretical total drug amount used in each formulation; and (2) entrapment
efficiency (EE%) to calculate the amount of DS entrapped in liposomes out of the actual total amount
in each liposome formulation after size reduction.
As shown by Figure 4a, DLE% of DS decreased with increasing drug/lipid ratio (p < 0.05) and that
was independent of phospholipid composition. For example, the DLE% of DS in HSPC-liposomes was
91.7%± 7.1% for the 5 mol%, and that was decreased to 48.12%± 12.0% for 15 mol% (p< 0.05). However,
DLE% for all liposomes was generally similar for the same drug/lipid ratio over the formulations
regardless phospholipid composition or PEGylation (Figure 3). Similar findings were observed for
paclitaxel (PTX)-liposomal formulations, processed by HPH (unpublished data). Whereas, in our
previous studies, using probe sonication for size reduction, lipid composition had a significant effect on
PTX entrapment efficiency [20]. This suggests that lipid composition and/or PEGylation had a minimal
influence on drug loading for liposomes that have undergone size reduction by HPH.
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Figure 4a also shows that DS loading reached a plateau phase in all formulations at approximately
7 mol%. More explicitly, for the 10 mol% formulations, DLE% values were around 60%–68%, which
correlates with 6–6.8 mol% actual entrapment of DS. Similar calculations for 15 mol% will lead to
a 7 mol% actual entrapment of DS. Therefore, no significant increase in DS loading was observed
by increasing the initial loading ratio of DS. These results became more obvious when we observed
that the EE% for all formulations were similar for both 15 mol% and 10 mol% formulations as shown
in Figure 4b (no significant differences; p > 0.05). This means that liposome bilayers were not able
to entrap greater DS proportions, i.e., a maximum interaction between DS and the phospholipid
was reached.
Figure 4b presents the entrapment efficiency of DS liposome formulations. Despite the decrease
in EE% for the 10 and 15 mol% compared to that of 5 mol%, the entrapment efficiencies were above
80%. This indicates that more than 80% of DS are entrapped in the liposomal vesicles of the final
formulations. In other words, less than 20% of the DS is free in the final formulation. This might
be considered—to an extent—a benefit for HPH as this size reduction technique was able to remove
most of the free drug from the final formulation. However, this also might initiate challenges during
the scale-up process, such as cleaning the kit after each preparation and validating methods to avoid
cross contamination.
We have previously studied the influence of lipid composition (such as HSPC:Ch and DPPC:Ch
in equimolar ratios) on the physicochemical properties of formulations and the entrapment efficiency
of paclitaxel (PTX) in the liposomes [20]. In that study, the entrapment efficiency of PTX was found to
be dependent on lipid composition with DPPC showing the highest loading efficiency (4.2 mol% at the
maximum concentration). Unlike PTX liposomes, DS entrapment showed significantly higher mol%,
almost a double of that found with PTX and without significant difference between HSPC and DPPC.
These differences might be due to the difference in the physiochemical properties between DS and
PTX, although both are lipophilic drugs. A main difference between DS and PTX is that the molecular
weight is two-times more for PTX than that of DS; this might explain the higher mol% entrapment
for DS.
It appears that the molecular weight of the loaded drug plays an important role in controlling
loading efficiency. For large molecules such as PTX, the maximum loading concertation was found to
be 3–4.2 mol% [15,20]. However, maximum loading concentration as high as 11.2 mol% was reported
for smaller molecules such as brucine [41]. Many other factors may also influence maximum loading,
such as the electrostatic interaction between the drug and polar head groups, which is beyond the
scope of the current study and more investigations are needed in the future.
3.4. Stability Studies in Horse Serum
Although the anticancer activity of DS has been known for many years, its application in
cancer therapy is limited by its instant degradation in the bloodstream (t1/2 < 4 min) [8]. The orally
administrated DS undergoes extensive first-pass metabolism in the liver; hence, the oral administration
of DS is not suitable for cancer treatment. This may explain the disappointing results from several oral
DS-based cancer clinical trials according to ClinicalTrials.gov (http://www.clinicaltrials.gov/).
Liposomes are already established as anticancer drug delivery systems with evidence of capability
to overcome the undesirable physicochemical properties of many anticancer drugs. Liposome-loaded
DS formulations can be applied intravenously to deliver the drug at cancer cells; this can avoid
liver-enrichment and protect the essential thiol groups on their way to the cancer site. In this study, DS
was encapsulated into liposomes and PEGylation was used to further extend the half-life of DS and
provide further prospective long circulation in the blood. The stability of DS was studied in horse
serum to investigate the efficiency of resulting PEGylated liposomes to protect DS.
As shown in Figure 5, both HSPC and DPPC liposomes demonstrated similar stability profiles, with
significantly (p < 0.05) enhanced stability of loaded DS compared to that of the free drug. Almost 70% of
free DS was degraded within the first 20 min, whereas an equal amount of loaded DS at both HSPC and
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DPPC liposomes took more than one hour to disappear. Furthermore, this time was extended to more
than three hours upon PEGylation, regardless of the phospholipid composition. These differences are
confirmed by the half-lives of DS in horse serum, which are extended by approximately three-fold for
DS-loaded HSPC (25.8 ± 6.5 min) and DPPC (28.7 ± 4.5 min) compared to that of free DS (9.7 ± 2.3 min).
The longest half-lives of DS were obtained after PEGylation; 71.9 ± 12.3 min for PEG-HSPC and
77.3 ± 9.6 min for PEG-DPPC (Figure 5b). Although the results show a slight difference between
HSPC and DPPC liposomes, no statistically significant difference (p > 0.05) was observed between
both phospholipids.
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PEGylation has been used in many studies to enhance the stability and prolong the circulation of
liposomes in vivo. The mechanisms protective action of PEG has been extensively investigated. One of
the most popular opinions is that the interactions of blood components with the liposome surface are
sterically hindered by the PEG coating the liposomes. This averts opsonization and uptake by the
mononuclear phagocyte system (MPS) [42,43]. Furthermore, surface modification of liposomes by a
soluble, well hydrated and chemically inert polymer (PEG), will decrease the surface hydrophobicity
and increase the repulsive interactions between colloidal particles (i.e., less liposome aggregation and
reduced binding of plasma proteins) [42,44].
PEG liposomal formulations have been successfully used to resolve drug delivery problems
of many drugs. For example, the first FDA-approved PEGylated liposomal formulation, Doxil®,
exhibited prolonged retention in vivo and improved therapeutic effects [45]. However, for some drugs,
such as vincristine, the result was unsatisfactory because its rapid leakage compromised its prolonged
circulation [43]. Therefore, using PEGylated liposomes should be subjected to in depth investigation,
on a case by case basis, depending on the drug and proposed application.
In this study, we found that PEGylated liposomes have a great potential for improving the stability
of DS and provide a prospective prolonged circulation in the blood. These results are also supported by
a recent study using DSPE-PEG2000-based PEGylated copper oleate liposome (Cu(OI)2-L) for targeted
delivery in cancer. Pharmacokinetic studies demonstrated that Cu(OI)2-L had a prolonged circulation
time compared to that of injected copper oleate solution [46]. However, no stability study results in
serum were shown and the feasibility (and compatibility) of combining DS with Cu+2 in the same
dosage form should be investigated in depth. For our study, more investigation is needed to explore
the long-term stability of the liposomal formulations and their ability to protect DS in vivo. This has
been already listed on to our future plans.
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3.5. Cytotoxicity Studies
When repetitively exposed to chemotherapeutics, cancer cells become more resistance and
aggressive. This is considered as one of the major hurdles to successful chemotherapy. In this study,
5-fluorouracil (5FU)-resistant colon cancer cell line H630R10 and their parental wide-type (sensitive)
cell line H630WT were used to determine the cytotoxicity of liposomes loaded with a range of DS
concentrations using the MTT assay. The resistant cancer cells are commonly cross-resistant to a
wide range of anticancer drugs, Figure 6 shows that H630R10 cell lines were not only resistant to
5FU, but also resistant to PTX at concentrations higher than 1000 nM, whereas the sensitive H630WT
were completely killed at concentration far below 1000 nM. These results are confirmed by IC50 being
above 1000 nM and 43.63 ± 15.21 for PTX (p < 0.01) in H630R10 and H630WT cell lines, respectively
(Table 2). The microscopy images taken 72 h after treatment also confirm that H630WT cell line, showing
apoptotic signs, were affected by both drugs 5FU and PTX. On the other hand, H630R10 cell lines were
not affected by both 5FU and PTX at the same corresponding concentrations and showed no features
of apoptosis (Figure 7).
Pharmaceutics 2019, 11, x  11 of 16 
 
cell line H630WT were used to determine the cytotoxicity of liposomes loaded with a range of DS 
concentrations using the MTT assay. The resistant cancer cells are commonly cross-resistant to a wide 
range of anticancer drugs, Figure 6 shows that H630R10 cell lines were not only resistant to 5FU, but 
also resistant to PTX at concentrations higher than 1000 nM, whereas the sensitive H630WT were 
completely killed at concentration far below 1000 nM. These results are confirmed by IC50 being above 
1000 nM and 43.63 ± 15.21 for PTX (p < 0.01) in H630R10 and H630WT cell lines, respectively (Table 2). 
The microscopy images taken 72 h after treatment also confirm that H630WT cell line, showing 
apoptotic signs, were affected by both drugs 5FU and PTX. On the other hand, H630R10 cell lines were 
not affected by both 5FU and PTX at the same corresponding concentrations and showed no features 
of apoptosis (Figure 7). 
 
Figure 6. Survival curves (MTT cytotoxicity assay) of colorectal cancer cell lines H630WT and H630R10 
with increasing concentrations of 5FU (a) and PTX (b) (n = 3 ± SD). 
Table 2. The IC50% values of DS formulations on both H630WT and H630R10 (n = 3 ± SD). 
 IC50 H630 WT (nM) H630 R10 (nM) 
5FU  3420 ± 630.0 >250000 
PTX 43.63 ± 15.21 >1000 
DS/Cu 57.736 ± 11.08 49.092 ± 8.20 
HSPC:Ch 75.544 ± 22.68 73.094 ± 12.28 
PEG:HSPC:Ch 69.076 ± 3.95 56.800 ± 3.21 
DPPC:Ch 76.273 ± 10.97 64.69 ± 10.88 
PEG:DPPC:Ch 71.289 ± 10.81 56.165 ± 21.16 
 
 
Figure 7. The morphology (× 100 magnification) of parental and resistant cells after 72 h of exposure 
to 5FU (100 μM), PTX (125 nM), and DS formulations (equivalent to 125 nm of DS). The arrows are 
pointing to features of apoptosis. 
Figure 6. Survival curves (MTT cytot xicity assay) of colorectal cancer cell li WT and H630R10
with increasing concentrations of 5FU (a) and PTX (b) (n = ).
Table 2. The IC50% values of DS formulations on both H630WT and H630R10 (n = 3 ± SD).
IC50 H630 WT (nM) H630 R10 (nM)
5FU 3420 ± 630.0 >250,000
PTX 43.63 ± 15.21 >1000
DS/Cu 57.736 ± 11.08 49.092 ± 8.20
HSPC:Ch 75.544 22.6 73.094 ± 12.28
PEG:HSPC:Ch 69.076 ± 3.95 56.800 ± 3.21
DPPC:Ch 76.273 ± 10.97 64.69 ± 10.88
PEG:DPPC:Ch 71.289 ± 10.81 56.165 ± 21.16
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Figure 8 shows the effect of DS liposome formulations on the viability of H630R10 and H630WT
cells. Cell viabilities of both cell lines were dependent on drug concentrations regardless phospholipid
type (p < 0.05). The empty liposomes (no DS), used as a negative control, had no effect on the
viability of both cell lines (Figure S3). This may suggest that the remaining ethanol resulting from the
preparation methods had no contribution to the cytotoxicity of DS-loaded formulations. For both cell
lines, DS completely inhibited the cell proliferation at the highest concentration (250 nM). Despite the
apparent trend showing that the cytotoxicity of DS alone on both cell lines was also higher than
that entrapped in liposome formulations, no statistically significant difference was found between
the free and encapsulated drug (Figure 8, Table 2). Similarly, IC50 values of DS formulations show
that the DS and its liposomal formulations were more toxic toward H630R10 than the sensitive cells
H630WT; these differences are statistically insignificant (p > 0.05). The apparent reduced cytotoxicity
of DS in liposome formulations might be attributed to the slow release profile of the drug from the
formulations (Figure S1), or to nutritious lipids forming liposomes. It is worth noting that PEGylation
had no significant effect (p > 0.05) on the cytotoxicity profiles of HSPC or DPPC DS-loaded liposomes
despite the apparent differences amongst IC50 values for PEGylated and non-PEGylated liposomes.
More investigation is necessary to study the influence of PEGylation on the cellular uptake of DS-loaded
liposomes. However, we believe that the cytotoxicity of DS-loaded liposomes is more dependent on
the DS release form the liposome rather than liposomal interaction with the cellular membrane.
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The cytotoxic effect of DS liposomal formulations was confirmed by microscopy images taken
after 72 h of exposure to the tested formulations (Figure 7). Both the H630WT and H630R10 cells
demonstrated apoptotic morphologies (cell blebbing and nuclear condensation and fragmentation) for
DS and its PEGylated liposomoal formulations. Similarly, as mentioned earlier, apoptotic morphology
was shown by H630WT after exposure to PTX. In contrast, PTX had no effect on H630R10 due to pan
chemoresistance. To assess any potential synergic effect between DS/Cu and 5FU or PTX, a combination
cytotoxicity has been performed using MTT assay. The resistant H630R10 cell lines were exposed to
serial concentrations of 5FU or PTX and DS/Cu or its PEGylated formulation PE :HSPC:Ch. As shown
in Figure 9, the combinatio between DS/Cu and 5FU or PTX r sulted in enhanced cytotoxicity which
was sig ificantly (p < 0.05) higher than the cytotoxic effect observed with each of the drugs applied
individu lly. More importantly, DS/Cu and its PEGylated liposomal formulation were able t reverse
the chemoresistance of H630R10. The IC50 values of the combinations were ignificantly (p > 0.05)
reduced compared to that of sol exposure to each drug. For exam le, th IC50 value for PEG:HSPC:Ch
combined with PTX was 21.81 ± 4.15 compared to that PTX alone (over 1000 nm).
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Figure 9. The MTT cytotoxicity assay. H630 R10 cell lines were exposed to different concentrations
of DS formulations in combination with (a) PTX (b) 5FU. (c) The IC50 values of DS formulations in
combination with (a) PTX (b) 5FU (n = 3 ± SD).
Drug-free formulations had no toxic effect on both colorectal cell lines. This has been confirmed
previously by several studies; drug-free liposomes displayed a neutral effect on both cancer and
normal cell lines in vitro [47]. This may be expected as liposomes are, in general, made of natural
biocompatible molecules similar to those forming cellular membranes. Furthermore, liposome vesicles
might enhance the efficacy of the drugs by binding to the cells and releasing the therapeutic molecules
in a sustained manner [47,48].
In conclusion, in this paper, we have reported the development of PEGylated liposomes of
disulfiram using ethanol-based proliposome methods followed by high-pressure homogenisation for
size reduction. DS-loaded PEGylated liposomes had relatively smaller sizes and significantly lower
polydispersity index than those of conventional liposomes. All liposomal formulations had good
entrapment efficiencies and maintained the cytotoxic effect of disulfiram in the presence of copper.
More importantly, we found that PEGylated liposomes significantly improved the stability of DS in
horse serum. Therefore, PEGylated liposomes might be able to act as potential nanocarriers of DS in
cancer therapy. The ability of PEGylated liposomes to protect DS and to provide prolonged circulation
in vivo has been already listed in our future plans.
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